Russ Mould, the investment director at AJ Bell, said Sycamore was likely to seek a swift sale of Boots to a private equity buyer in the first instance as it will care more about making money now rather than later
Yang L, Chen L, Li D, Xu H, Chen J, Min X, He M, Wu T, Zhong J, Yang H
These before-and-after results highlight the powerful, sustainable changes possible with physician-supervised semaglutide and tirzepatide programs
UK considerations NHS and MHRA guidance The UK health authorities have clear positions on weight loss treatments: The NHS offers GLP-1 medications through specialist weight management services for eligible patients MHRA has approved Wegovy, Saxenda, and Mounjaro based on comprehensive safety and efficacy data No GLP-1 patch products have received MHRA approval as weight loss treatments The MHRA has issued warnings about misleading claims in weight loss supplements Cost and access in the UK The financial aspect is a significant consideration for many: NHS provision : Limited availability through specialist weight management services with strict eligibility criteria Private prescriptions : 150-300 monthly, depending on medication and provider Commercial patches : 12-70 monthly, depending on brand and quantity While patches appear less expensive, they lack evidence of effectiveness, making them poor value regardless of price
NVQ Beauty Therapy Level 3)
& Mulvihill, E
